Vyxeos
Prescribing
Information (PI) PI
  • THE PATIENTS
  • THE FORMULATION
  • THE DATA
  • THE DOSING
  • THE RESOURCES
  • PI
play

TOGETHER.
LONGER.†

video

Vyxeos Liposomal is the first chemotherapy to significantly increase median overall survival (OS)
vs conventional chemotherapy** in patients with high-risk* AML1
(KM-estimated median OS: Vyxeos Liposomal, 9.56 months; conventional chemotherapy, 5.96 months (HR: 0.69, 95% CI: 0.52-0.90, p=0.005 [2-sided])1,2)

Vyxeos Liposomal is indicated for the treatment of adults with newly diagnosed,
therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)2

background
A panel discussion: Have the new classifications improved the way we manage patients?
background
A panel discussion: Why is real-world evidence important to our daily practice?
background
A panel discussion: How has Vyxeos’ real-world evidence affected our daily clinical practice?
background
Reinforcing Clinical Results
in the Real-World
background
Vyxeos Liposomal Data Presentation
background

SmPC and Prescribing Information
is available in the menu

What Makes the
Mechanism of Action Different?
background
5-Year Follow-Up
Clinical Summary
LAYING THE
foudation
TOWARDS LONG-TERM SURVIVAL
IN HIGH-RISK* AML
This website is intended for European Healthcare Professionals only.
REFERENCES
  • Lancet JE et al. J Clin Oncol 2018;36(26):2684-92.
  • Vyxeos Liposomal. European Summary of Product Characteristics.
  • † Superior overall survival vs conventional chemotherapy** in patients with high-risk * AML 1
  • * High-risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
  • ** Comparator arm conventional chemotherapy is 7+3 in induction, 5+2 in second induction and consolidation where given

ADVERSE EVENTS REPORTING

Adverse events should be reported. Healthcare Professionals are asked to report any suspected adverse events via their national reporting system. For the UK, reporting forms and information can be found at yellowcard.mhra.gov.uk, or search for Yellow Card MHRA in the Google Play or Apple App Store. Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

Job code: INT-VYX-2200141
Date of Preparation: July 2023
Vyxeos
Vyxeos
  • Contact Us
  • Terms of
    Use
  • Privacy
    Statement
  • Cookie
    Policy
  • Prescribing
    Information (PI)
You are being directed to the Jazz corporate website.

Follow link
You are being directed to an external website.
Follow link
This Jazz Pharmaceuticals website has been created for healthcare professionals only.

Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.

I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL

I AM A UK HEALTHCARE PROFESSIONAL

I AM A US HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the UK

https://vyxeos.co.uk
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the US only

https://vyxeospro.com
For European patients and the general public

For more information:

Patient information leaflet
EMA - Information on Vyxeos Liposomal

By clicking here you will be taken to the European Medicines Agency’s external website

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.

Prescribing Information